PL3087095T3 - Antagoniści fcrn i sposoby stosowania - Google Patents

Antagoniści fcrn i sposoby stosowania

Info

Publication number
PL3087095T3
PL3087095T3 PL14827372T PL14827372T PL3087095T3 PL 3087095 T3 PL3087095 T3 PL 3087095T3 PL 14827372 T PL14827372 T PL 14827372T PL 14827372 T PL14827372 T PL 14827372T PL 3087095 T3 PL3087095 T3 PL 3087095T3
Authority
PL
Poland
Prior art keywords
methods
fcrn antagonists
fcrn
antagonists
Prior art date
Application number
PL14827372T
Other languages
English (en)
Inventor
Peter Ulrichts
Christophe Blanchetot
Torsten Dreier
Johannes De Haard
E. Sally Ward Ober
Nicolas G.H. Ongenae
Original Assignee
Argenx Bvba
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347464&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3087095(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argenx Bvba, The Board Of Regents Of The University Of Texas System filed Critical Argenx Bvba
Publication of PL3087095T3 publication Critical patent/PL3087095T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
PL14827372T 2013-12-24 2014-12-23 Antagoniści fcrn i sposoby stosowania PL3087095T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920547P 2013-12-24 2013-12-24
EP14827372.5A EP3087095B1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use
PCT/US2014/072087 WO2015100299A1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use

Publications (1)

Publication Number Publication Date
PL3087095T3 true PL3087095T3 (pl) 2020-03-31

Family

ID=52347464

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14827372T PL3087095T3 (pl) 2013-12-24 2014-12-23 Antagoniści fcrn i sposoby stosowania

Country Status (23)

Country Link
US (3) US10316073B2 (pl)
EP (2) EP3087095B1 (pl)
JP (2) JP6554473B2 (pl)
KR (3) KR102452173B1 (pl)
CN (2) CN112142843A (pl)
AU (1) AU2014369999B2 (pl)
BR (1) BR112016014810B1 (pl)
CA (1) CA2934644C (pl)
DK (1) DK3087095T3 (pl)
EA (1) EA035324B1 (pl)
ES (1) ES2742682T3 (pl)
FI (1) FIC20230003I1 (pl)
FR (1) FR23C1004I2 (pl)
HU (2) HUE046822T2 (pl)
IL (1) IL246223B (pl)
LT (2) LT3087095T (pl)
MX (1) MX368804B (pl)
NL (1) NL301203I2 (pl)
NZ (1) NZ722055A (pl)
PL (1) PL3087095T3 (pl)
PT (1) PT3087095T (pl)
SG (2) SG10202009832XA (pl)
WO (1) WO2015100299A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102452173B1 (ko) 2013-12-24 2022-10-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn 길항제 및 사용방법
EP3268391B1 (en) * 2015-03-09 2021-08-11 argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
CN109689685A (zh) 2016-07-08 2019-04-26 斯塔滕生物技术有限公司 抗apoc3抗体及其使用方法
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CA3045797A1 (en) * 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP7422659B2 (ja) * 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
CA3101462A1 (en) * 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) * 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
WO2020054979A1 (ko) * 2018-09-12 2020-03-19 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
SG11202112010RA (en) * 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
CN113769058A (zh) * 2020-06-10 2021-12-10 上海宝济药业有限公司 一种药物组合及其应用
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2022271814A2 (en) 2021-06-23 2022-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
AU2023208882A1 (en) 2022-01-18 2024-05-09 argenx BV Galectin-10 antibodies
WO2023156614A1 (en) 2022-02-21 2023-08-24 argenx BV Methods for treating myositis using fcrn antagonists
WO2023198806A1 (en) 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
WO2023215838A1 (en) 2022-05-05 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ES2194973T3 (es) 1995-01-17 2003-12-01 Brigham & Womens Hospital Transporte de inmunogenes transepitelial especifico del receptor.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
DK1370288T3 (da) 2000-11-20 2012-03-05 Canadian Blood Services Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3945281B2 (ja) 2002-03-19 2007-07-18 富士ゼロックス株式会社 画像形成装置
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
KR100960560B1 (ko) 2002-09-27 2010-06-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006035600A1 (ja) 2004-09-30 2006-04-06 Brother Kogyo Kabushiki Kaisha 無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
SI2185589T1 (sl) * 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
US8732170B2 (en) 2007-11-27 2014-05-20 Zettics, Inc. Method and apparatus for real-time multi-dimensional reporting and analyzing of data on application level activity and other user information on a mobile data network
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) * 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
LT2486141T (lt) * 2009-10-07 2018-05-25 Macrogenics, Inc. Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
GB201111291D0 (en) 2011-06-30 2011-08-17 Agco Int Gmbh Engine control system
BR112014010008A2 (pt) 2011-10-26 2018-09-04 Novartis Ag anticorpos monoclonais, seus usos e ácidos nucleicos
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR20150030693A (ko) 2012-07-05 2015-03-20 제넨테크, 인크. 발현 및 분비 시스템
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
EP3663763B1 (en) 2013-11-26 2022-02-16 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
KR102452173B1 (ko) 2013-12-24 2022-10-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn 길항제 및 사용방법
RU2725442C2 (ru) 2014-09-17 2020-07-02 Аффибоди Аб Новые полипептиды
KR102483016B1 (ko) 2015-01-30 2023-01-03 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
EP3268391B1 (en) 2015-03-09 2021-08-11 argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
AU2016262100B2 (en) 2015-05-12 2021-10-14 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP7118884B2 (ja) 2015-07-17 2022-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
JP7422659B2 (ja) 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
WO2020236695A1 (en) 2019-05-17 2020-11-26 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases

Also Published As

Publication number Publication date
WO2015100299A1 (en) 2015-07-02
NL301203I2 (nl) 2023-05-24
EA201691304A1 (ru) 2016-10-31
KR20240033084A (ko) 2024-03-12
KR102452173B1 (ko) 2022-10-17
LT3087095T (lt) 2019-09-10
FIC20230003I1 (fi) 2023-01-19
EA035324B1 (ru) 2020-05-28
NZ722055A (en) 2020-02-28
SG11201605203UA (en) 2016-07-28
CA2934644A1 (en) 2015-07-02
EP3087095B1 (en) 2019-08-07
FR23C1004I1 (fr) 2023-03-10
LTPA2022014I1 (pl) 2022-12-12
US20180179258A1 (en) 2018-06-28
BR112016014810A2 (pt) 2017-09-19
KR20160111937A (ko) 2016-09-27
FR23C1004I2 (fr) 2024-01-05
IL246223B (en) 2021-06-30
NL301203I1 (pl) 2022-11-09
US20150218239A1 (en) 2015-08-06
AU2014369999A1 (en) 2016-07-07
CN112142843A (zh) 2020-12-29
CN106103476B (zh) 2020-11-27
HUE046822T2 (hu) 2020-03-30
IL246223A0 (en) 2016-07-31
MX2016008399A (es) 2016-12-15
JP6554473B2 (ja) 2019-07-31
CN106103476A (zh) 2016-11-09
KR20220152546A (ko) 2022-11-16
PT3087095T (pt) 2019-10-09
SG10202009832XA (en) 2020-11-27
JP2017501725A (ja) 2017-01-19
EP3087095A1 (en) 2016-11-02
CA2934644C (en) 2023-11-21
JP2019076103A (ja) 2019-05-23
HUS2200048I1 (hu) 2022-12-28
MX368804B (es) 2019-10-17
EP3626738A1 (en) 2020-03-25
DK3087095T3 (da) 2019-10-28
US10316073B2 (en) 2019-06-11
ES2742682T3 (es) 2020-02-17
BR112016014810B1 (pt) 2023-12-26
US11505585B2 (en) 2022-11-22
AU2014369999B2 (en) 2019-12-12
US20220275035A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
HUS2200048I1 (hu) FcRn antagonisták és alkalmazásaik
IL290547A (en) Antibodies and methods of use
HK1216380A1 (zh) 附接裝置以及使用和製造的相關聯的方法
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HK1225612A1 (zh) 抗ly6e抗體及使用方法
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same